Beximco makes profit of Tk 77 per Covid-19 vaccine

Beximco Pharmaceuticals in Bangladesh has made a profit of around Tk 77 by importing the Oxford–AstraZeneca Covid-19 vaccine developed by the Serum Institute of India. The pharmaceutical company made the profit per vaccine excluding all costs.

A source at Dhaka Stock Exchange (DSE) came up with the information on Sunday (May 2).

According to the DSE website, Beximco Pharma made a profit of Tk 38.37 crore by providing 50 lakh Covid-19 vaccine to the government during the January-March period. As per that estimate, the pharmaceutical company made the profit per vaccine excluding all costs, the source said.